002020.SZ
京新药业
SZSE · Healthcare · C 制造业 · CN
CNY 12.69
−3.72%Year over year
Reported trailing growth
- Revenue
- -0.4%
- EBITDA
- —
- EBIT
- +3.5%
- EPS
- +10.2%
- Free cash flow
- +136.2%
- Operating cash flow
- +49.4%
Forward estimates
Based on analyst estimates
- Revenue
- +6.5%
- EBITDA
- +0.7%
- EPS
- -2.8%
Three-year CAGR
- Revenue
- +2.5%
- EBITDA
- +6.9%
- EBIT
- +4.5%
- Net income
- +4.6%
- EPS
- +6.1%
- Free cash flow
- +19.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026